drugset
drugset / Trial / NCT01013415

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

NCT01013415 ↗

Phase 1 Completed 17 enrolled University of Pennsylvania
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out the safety and activity of an experimental anti-HIV treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant interleukin2).

Timeline

Start
2001-09
Primary completion
2005-06
Completion
2021-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CD4-zeta gene modified T cells Cell therapy — —

Indications

HIV infectious disease